AGENUS INC Proceeds from Sale of Intangible Assets
AGENUS INC (AGEN) reported Proceeds from Sale of Intangible Assets of $63.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfIntangibleAssets · last filed 2026-08-07
- AGENUS INC proceeds from sale of intangible assets for the quarter ending 2026-06-30 was $0.00.
- AGENUS INC proceeds from sale of intangible assets for the quarter ending 2026-03-31 was $63.92M.
- AGENUS INC proceeds from sale of intangible assets for the quarter ending 2025-06-30 was $0.00.
- AGENUS INC proceeds from sale of intangible assets for the quarter ending 2025-03-31 was $0.00.
- AGENUS INC proceeds from sale of intangible assets for fiscal 2011 was $0.00.
- AGENUS INC proceeds from sale of intangible assets for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
- AGENUS INC proceeds from sale of intangible assets for fiscal 2009 was $2.34M.
| Period end | Proceeds from Sale of Intangible Assets 3 month | Proceeds from Sale of Intangible Assets 6 month | Proceeds from Sale of Intangible Assets 9 month | Proceeds from Sale of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $63.92M 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | $63.92M 10-Q · filed 2026-05-11 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $0.00 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | |||
| 2011-12-31 | $0.00 10-K · filed 2012-03-06 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-06 | $0.00 derived: sum of 2 quarters · filed 2012-03-06 | $0.00 10-K · filed 2012-03-06 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $0.00 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $2.34M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |